Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis

NCT03711448 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Dijon as lead sponsor.

NCT NCT03711448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03711448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
Lead sponsor
Centre Hospitalier Universitaire Dijon
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2019
Completion date
September 11, 2024
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients relapsing refractory giant cell arteritis